FDA Brief

Warning letters Drugs

FDA warning letter to

Neoingenium Labs, SA de CV

High riskIssued Mar 31, 2021Posted Apr 6, 2021Center for Drug Evaluation and Research

Neoingenium Labs' cleansepure hand sanitizer, labeled 70% ethanol, contained 58% methanol and only 9.6% ethanol, FDA testing found.

What happened

FDA tested a batch of cleansepure hand sanitizer after it was detained and refused admission at the U.S. border. The product was labeled to contain 70% ethanol, but FDA found an average of 9.6% ethanol and 58% methanol. FDA also found the product was an unapproved new drug and misbranded.

What FDA found

  1. The hand sanitizer was adulterated because its labeled active ingredient, ethanol, was replaced in whole or in part with methanol.

    FD&C Act section 501(d)(2), 21 U.S.C. 351(d)(2)
  2. The methanol substitution showed that quality assurance at the facility was not working under CGMP.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  3. The product was an unapproved new drug sold without FDA approval.

    FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)
  4. The label was false or misleading because it claimed 70% ethanol but the product had much less ethanol and undeclared methanol.

    FD&C Act section 502(a), 21 U.S.C. 352(a)
  5. The label did not declare methanol as an ingredient.

    FD&C Act section 502(e)(1)(A), 21 U.S.C. 352(e)(1)(A)
  6. The product was dangerous to health when used as labeled because it contained methanol.

    FD&C Act section 502(j), 21 U.S.C. 352(j)

What FDA wants

FDA asks the company to investigate how the product was substituted with methanol and to provide supplier details, a reconciliation of hand sanitizer batches shipped to the U.S., and complete batch records. The company must respond in writing within 15 working days.

Who should pay attention

  • brands and distributors that sell imported hand sanitizer
  • U.S. companies using contract manufacturers in Mexico
  • retailers and consumers of alcohol-based hand sanitizers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. World Perfumes Inc.

    World Perfumes failed to test drug ingredients for toxic contaminants and had inadequate water, FDA says.

    High risk
  2. RNA Bio/Pharma, Incorporated

    FDA found RNA Bio/Pharma failed to test homeopathic oral liquid drugs for dangerous contaminants and did not validate its water system.

    High risk
  3. Kabana Skin Care LLC

    Kabana Skin Care failed to test OTC drug ingredients and finished products, prompting a recall and halt of U.S. drug manufacturing.

    High risk
  4. Ningbo Riway Industrial Co., Ltd.

    Ningbo Riway Industrial, an OTC drug maker in China, was cited for manufacturing-practice failures and unapproved antiseptic wipes.

    High risk